Josephine Harrington
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Josephine Harrington has a total of 370 co-authors. Here are the top co-authors by number of shared publications:
- Javed Butler
Baylor Scott and White Research Institute, Baylor Scott and White Health, Dallas, Texas
7 shared publications W. Schuyler Jones
Duke Clinical Research Institute, Durham, North Carolina, USA
6 shared publications- Christopher B. Granger
Duke University
5 shared publications G. Michael Felker
5 shared publicationsJames L. Januzzi
5 shared publications- Robert J. Mentz
Division of Cardiology, Department of Medicine, Duke University School of Medicine
5 shared publications
Latest Publications
- 1 November 2026
- Published by Wolters Kluwer Health in Circulation: Population Health and Outcomes
- Vol. 19 (11)
Use of Anticoagulation Among Patients With Atrial Fibrillation or Atrial Flutter in the United States
BACKGROUND: Oral anticoagulation (OAC) remains underused in patients with atrial fibrillation or flutter at high risk of ischemic stroke. We aimed to characterize documented OAC prescribing at diagnosis and during 1-year follow-up and identify factors associated with baseline OAC prescribing. METHODS: Using electronic health records from 7 US health systems participating in the National Patient-Centered Clinical Research Network between 2015 and 2019, we identified patients with newly diagnosed atrial fibrillation at high risk of ischemic stroke (CHA 2 DS 2 -VASc score ≥2 for men or ≥3 for women). The primary outcomes were documented OAC prescription at baseline and during 1-year follow-up. Exposures included demographic, clinical, and health-system characteristics. Multivariable logistic regression was used to identify factors associated with baseline OAC prescribing and loss of documented OAC prescribing during follow-up. RESULTS: Among 161 295 patients (median age, 76 years [interquartile range, 68–82]; 70 327 [43.6%] women), 92 518 (57.4%) had a documented OAC prescription at baseline, increasing from 56.6% in 2015 to 62.6% in 2019. Among those with a documented baseline OAC prescription, 45.6% had no documented OAC prescription during 1-year follow-up. Among 68 777 patients without a documented baseline OAC prescription, 12.5% had an OAC prescription documented during follow-up. Dementia (odds ratio, 0.58 [95% CI, 0.56–0.61]), prior major bleeding (odds ratio, 0.69 [95% CI, 0.63–0.75]), and renal disease (odds ratio, 0.84 [95% CI, 0.81–0.88]) were associated with lower odds of baseline OAC prescribing, whereas heart failure was associated with higher odds (odds ratio, 1.40 [95% CI, 1.37–1.43]). CONCLUSIONS: Among patients with newly diagnosed atrial fibrillation at high risk for ischemic stroke, OAC prescribing at diagnosis was suboptimal, and loss of documented OAC prescribing was common during the first year. Baseline OAC use was more strongly associated with bleeding risk, frailty, and comorbidity burden, and less consistently aligned with ischemic stroke risk.
- 1 November 2026
- Published by Wolters Kluwer Health in Circulation: Population Health and Outcomes
- Vol. 19 (11)
Use of Anticoagulation Among Patients With Atrial Fibrillation or Atrial Flutter in the United States
BACKGROUND: Oral anticoagulation (OAC) remains underused in patients with atrial fibrillation or flutter at high risk of ischemic stroke. We aimed to characterize documented OAC prescribing at diagnosis and during 1-year follow-up and identify factors associated with baseline OAC prescribing. METHODS: Using electronic health records from 7 US health systems participating in the National Patient-Centered Clinical Research Network between 2015 and 2019, we identified patients with newly diagnosed atrial fibrillation at high risk of ischemic stroke (CHA 2 DS 2 -VASc score ≥2 for men or ≥3 for women). The primary outcomes were documented OAC prescription at baseline and during 1-year follow-up. Exposures included demographic, clinical, and health-system characteristics. Multivariable logistic regression was used to identify factors associated with baseline OAC prescribing and loss of documented OAC prescribing during follow-up. RESULTS: Among 161 295 patients (median age, 76 years [interquartile range, 68–82]; 70 327 [43.6%] women), 92 518 (57.4%) had a documented OAC prescription at baseline, increasing from 56.6% in 2015 to 62.6% in 2019. Among those with a documented baseline OAC prescription, 45.6% had no documented OAC prescription during 1-year follow-up. Among 68 777 patients without a documented baseline OAC prescription, 12.5% had an OAC prescription documented during follow-up. Dementia (odds ratio, 0.58 [95% CI, 0.56–0.61]), prior major bleeding (odds ratio, 0.69 [95% CI, 0.63–0.75]), and renal disease (odds ratio, 0.84 [95% CI, 0.81–0.88]) were associated with lower odds of baseline OAC prescribing, whereas heart failure was associated with higher odds (odds ratio, 1.40 [95% CI, 1.37–1.43]). CONCLUSIONS: Among patients with newly diagnosed atrial fibrillation at high risk for ischemic stroke, OAC prescribing at diagnosis was suboptimal, and loss of documented OAC prescribing was common during the first year. Baseline OAC use was more strongly associated with bleeding risk, frailty, and comorbidity burden, and less consistently aligned with ischemic stroke risk.
- 29 June 2026
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 47 (38) , 5593-5596
Weight loss, exercise haemodynamics, and health status with incretin therapy for heart failure with preserved ejection fraction and obesity
- 29 June 2026
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 47 (38) , 5593-5596
Weight loss, exercise haemodynamics, and health status with incretin therapy for heart failure with preserved ejection fraction and obesity
- Open Access
- 29 June 2026
- Published by Elsevier in JACC: Advances
- Vol. 5 (8) , 102954
Clinical Patterns and Appropriateness of Apixaban Dosing in Patients With Atrial Fibrillation
- 29 June 2026
- Published by Elsevier in JACC: Advances
- Vol. 5 (8) , 102954
Open AccessClinical Patterns and Appropriateness of Apixaban Dosing in Patients With Atrial Fibrillation
- 6 June 2026
- Published by Springer Nature in Heart Failure Reviews
- Vol. 31 (1)
Association between SGLT2 inhibitors and outcomes after heart transplant in patients with type 2 diabetes: A systematic review and meta-analysis
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are recommended for multiple populations-type 2 diabetes (T2D), chronic kidney disease, and heart failure-but their role after heart transplant (HTX) remains unclear. We searched PubMed, Cochrane, and Embase for studies of HTX recipients with T2D comparing outcomes in SGLT2i users vs. non-users. Outcomes of interest were all-cause mortality, urinary tract infection (UTI), and estimated glomerular filtration rate (eGFR) change from baseline. Odds ratios (ORs) and adjusted hazard ratios (aHRs) with 95% confidence intervals (CIs) were pooled using a random-effects model for binary outcomes. Three retrospective observational studies were included in the all-cause mortality meta-analysis, four in the UTI incidence meta-analysis, and five in the qualitative analysis evaluating eGFR change (n = 3,564). Mean follow-up ranged from 9 to 83 months. SGLT2i use was associated with a lower risk of all-cause mortality compared with non-use in both unadjusted (OR 0.43; 95% CI 0.26-0.71; p < 0.001; I² = 79%) and adjusted analyses (aHR 0.69; 95% CI 0.51-0.93; p = 0.02; I² = 20%), without increasing the risk of UTI (OR 0.77; 95% CI 0.14-4.05; p = 0.75; I² = 48%). Most studies suggested stable or increased eGFR from baseline with SGLT2i exposure. SGLT2i use, compared with non-use, was associated with lower all-cause mortality without an increased incidence of UTIs in HTX recipients with T2D. Additionally, the pooled data suggest a possible renal benefit. The totality of these observational data, despite their limitations, provide important context for ongoing SGLT2i use following HTX.
- 6 June 2026
- Published by Springer Nature in Heart Failure Reviews
- Vol. 31 (1)
Association between SGLT2 inhibitors and outcomes after heart transplant in patients with type 2 diabetes: A systematic review and meta-analysis
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are recommended for multiple populations-type 2 diabetes (T2D), chronic kidney disease, and heart failure-but their role after heart transplant (HTX) remains unclear. We searched PubMed, Cochrane, and Embase for studies of HTX recipients with T2D comparing outcomes in SGLT2i users vs. non-users. Outcomes of interest were all-cause mortality, urinary tract infection (UTI), and estimated glomerular filtration rate (eGFR) change from baseline. Odds ratios (ORs) and adjusted hazard ratios (aHRs) with 95% confidence intervals (CIs) were pooled using a random-effects model for binary outcomes. Three retrospective observational studies were included in the all-cause mortality meta-analysis, four in the UTI incidence meta-analysis, and five in the qualitative analysis evaluating eGFR change (n = 3,564). Mean follow-up ranged from 9 to 83 months. SGLT2i use was associated with a lower risk of all-cause mortality compared with non-use in both unadjusted (OR 0.43; 95% CI 0.26-0.71; p < 0.001; I² = 79%) and adjusted analyses (aHR 0.69; 95% CI 0.51-0.93; p = 0.02; I² = 20%), without increasing the risk of UTI (OR 0.77; 95% CI 0.14-4.05; p = 0.75; I² = 48%). Most studies suggested stable or increased eGFR from baseline with SGLT2i exposure. SGLT2i use, compared with non-use, was associated with lower all-cause mortality without an increased incidence of UTIs in HTX recipients with T2D. Additionally, the pooled data suggest a possible renal benefit. The totality of these observational data, despite their limitations, provide important context for ongoing SGLT2i use following HTX.
- Open Access
- 3 April 2026
- Published by Elsevier in American Heart Journal
- Vol. 298, 107439
Economic burden associated with systemic inflammation in patients with HFmrEF/HFpEF
- 3 April 2026
- Published by Elsevier in American Heart Journal
- Vol. 298, 107439
Open AccessEconomic burden associated with systemic inflammation in patients with HFmrEF/HFpEF
- 10 March 2026
- Published by Wolters Kluwer Health in Current Opinion in Cardiology
- Vol. 41 (3) , 147-156
Weight loss as the optimal cardiometabolic management strategy for preventing and treating heart failure
Purpose of review: To synthesize current evidence supporting intentional weight reduction as a cardiometabolic strategy for treating and preventing heart failure (HF) across the ejection-fraction spectrum, examine the influence of baseline obesity on treatment effects of established HF therapies, and highlight key knowledge gaps and future research directions. Recent findings: Visceral adipose tissue, central obesity, and dysfunctional adipose mass are linked to the development and progression of HF with preserved ejection fraction (HFpEF). Recent trials show that incretin-based therapies (semaglutide, tirzepatide) improve exercise capacity, symptoms, and quality of life in HFpEF, and potentially reduce HF events. Patients with higher degrees of obesity may derive greater benefit from incretin-based therapies and other guideline-directed therapies, including mineralocorticoid receptor antagonists (MRA), sodium-glucose transport 2 (SGLT2) inhibitors, and angiotensin receptor-neprilysin inhibitor (ARNI). While observational studies suggest intentional weight loss may lower HF risk, randomized trials of antiobesity medications have yet to further clarify this potential benefit. Summary: Weight loss is currently recommended as an optimal strategy for individuals with obesity and HFpEF, given consistent benefits for exercise capacity, functional status, and quality of life, with a potential for reducing clinical events. Intentional weight loss impact in HFrEF and its role in primary HF prevention remains uncertain. Large, well designed cardiovascular outcome trials of intentional weight-loss interventions in populations with obesity and HF, or obesity and elevated HF risk, are needed to establish clinical efficacy and better define individuals who benefit from those interventions across the spectrum of ejection fraction.
- 10 March 2026
- Published by Wolters Kluwer Health in Current Opinion in Cardiology
- Vol. 41 (3) , 147-156
Weight loss as the optimal cardiometabolic management strategy for preventing and treating heart failure
Purpose of review: To synthesize current evidence supporting intentional weight reduction as a cardiometabolic strategy for treating and preventing heart failure (HF) across the ejection-fraction spectrum, examine the influence of baseline obesity on treatment effects of established HF therapies, and highlight key knowledge gaps and future research directions. Recent findings: Visceral adipose tissue, central obesity, and dysfunctional adipose mass are linked to the development and progression of HF with preserved ejection fraction (HFpEF). Recent trials show that incretin-based therapies (semaglutide, tirzepatide) improve exercise capacity, symptoms, and quality of life in HFpEF, and potentially reduce HF events. Patients with higher degrees of obesity may derive greater benefit from incretin-based therapies and other guideline-directed therapies, including mineralocorticoid receptor antagonists (MRA), sodium-glucose transport 2 (SGLT2) inhibitors, and angiotensin receptor-neprilysin inhibitor (ARNI). While observational studies suggest intentional weight loss may lower HF risk, randomized trials of antiobesity medications have yet to further clarify this potential benefit. Summary: Weight loss is currently recommended as an optimal strategy for individuals with obesity and HFpEF, given consistent benefits for exercise capacity, functional status, and quality of life, with a potential for reducing clinical events. Intentional weight loss impact in HFrEF and its role in primary HF prevention remains uncertain. Large, well designed cardiovascular outcome trials of intentional weight-loss interventions in populations with obesity and HF, or obesity and elevated HF risk, are needed to establish clinical efficacy and better define individuals who benefit from those interventions across the spectrum of ejection fraction.
- 20 November 2025
- Published by Elsevier in JACC: Heart Failure
- Vol. 14 (3)
Heart Failure With Preserved Ejection Fraction Across the Spectrum of Body Mass Index
- 20 November 2025
- Published by Elsevier in JACC: Heart Failure
- Vol. 14 (3)
Heart Failure With Preserved Ejection Fraction Across the Spectrum of Body Mass Index
- 17 November 2025
- p. 102768
Heart Failure With Preserved Ejection Fraction Across the Spectrum of Body Mass Index: Hemodynamic and Echocardiographic Characteristics and Outcomes.
Limited data are available on the relationship between body mass index (BMI) and heart failure (HF) physiology or clinical outcomes in patients with heart failure with preserved ejection fraction (HFpEF). This study aims to assess the relationship between BMI and echocardiographic and hemodynamic measures as well as the risk of HF hospitalization and death. This analysis was performed using a large multicenter registry of patients with diagnosed HFpEF in PCORnet (National Patient-Centered Clinical Research Network) from 2012 to 2018 who had undergone either echocardiography or invasive right heart catheterization. Of the 149,027 patients with HFpEF, 1.8% were underweight, 20.5% had a normal BMI, 27.9% were overweight, 22.1% had class 1 obesity, 13.3% had class 2, and 14.4% had class 3 obesity. The median follow-up time was 3.5 years. Higher BMI was associated with significant increases in multiple echocardiographic and hemodynamic markers of HF severity, including larger left atrial diameter, left ventricular end-diastolic diameter, and higher mean pulmonary artery pressure and pulmonary capillary wedge pressure (P < 0.001 for all). Higher BMI was associated with a significant and linear increase in the risk of HF hospitalization. In contrast, a sharp L-shaped relationship was observed between BMI and death, such that patients who were underweight had the highest risk of death and increasing BMI >30 kg/m2 was associated with a stable risk of death compared with patients who were overweight. In these large, real-world, multicenter analyses, higher BMI was associated with adverse hemodynamic and structural cardiac changes, a linear increase in the risk of HF hospitalization, and a stable risk of death.
- 17 November 2025
- p. 102768
Heart Failure With Preserved Ejection Fraction Across the Spectrum of Body Mass Index: Hemodynamic and Echocardiographic Characteristics and Outcomes.
Limited data are available on the relationship between body mass index (BMI) and heart failure (HF) physiology or clinical outcomes in patients with heart failure with preserved ejection fraction (HFpEF). This study aims to assess the relationship between BMI and echocardiographic and hemodynamic measures as well as the risk of HF hospitalization and death. This analysis was performed using a large multicenter registry of patients with diagnosed HFpEF in PCORnet (National Patient-Centered Clinical Research Network) from 2012 to 2018 who had undergone either echocardiography or invasive right heart catheterization. Of the 149,027 patients with HFpEF, 1.8% were underweight, 20.5% had a normal BMI, 27.9% were overweight, 22.1% had class 1 obesity, 13.3% had class 2, and 14.4% had class 3 obesity. The median follow-up time was 3.5 years. Higher BMI was associated with significant increases in multiple echocardiographic and hemodynamic markers of HF severity, including larger left atrial diameter, left ventricular end-diastolic diameter, and higher mean pulmonary artery pressure and pulmonary capillary wedge pressure (P < 0.001 for all). Higher BMI was associated with a significant and linear increase in the risk of HF hospitalization. In contrast, a sharp L-shaped relationship was observed between BMI and death, such that patients who were underweight had the highest risk of death and increasing BMI >30 kg/m2 was associated with a stable risk of death compared with patients who were overweight. In these large, real-world, multicenter analyses, higher BMI was associated with adverse hemodynamic and structural cardiac changes, a linear increase in the risk of HF hospitalization, and a stable risk of death.